Masimo saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 78 to 88.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buy zone in heavy trade.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 31% to 44%. Revenue rose from 5% to 9%.
Masimo earns the No. 4 rank among its peers in the Medical-Systems/Equipment industry group. Intuitive Surgical is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
